Study S001699

Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04909333
Acronym: FAST
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: COMPLETED
Enrollment: 29
Start: 2021-04-29
Primary completion: 2024-04-30
Lead sponsor: University Hospital, Basel, Switzerland
Conditions: Endogenous Hyperinsulinism
Interventions: DRUG:Exenatide; DRUG:0.9% saline solution
Results posted: FALSE

Registered primary outcomes

time to symptomatic hypoglycemia after exenatide test compared to placebo [within 4 hours after injection]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011293	Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study. Hepprich M, European journal of endocrinology	2025	Randomized trial	PMID 40747712 DOI	cites ClinicalTrials.gov:NCT04909333; registry reference DERIVED:40747712
R0043934	SAT-064 Copeptin Levels at Baseline and in Response to Short-Acting GLP-1 Receptor Agonists in Patients with Endogenous Hyperinsulinemic Hypoglycemia and Healthy Controls - A Secondary Analysis Svenja Leibnitz, Journal of the Endocrine Society	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04909333